Most Read Articles
Rachel Soon, 29 May 2019

AstraZeneca has announced plans to invest over US$125 million (RM500 million) in Malaysia over the next 5 years, with a focus on patient-centred innovation, local talent development and new robotic and cognitive technologies.

Tristan Manalac, 29 May 2019
Beta blockers (BB) and renin-angiotensin inhibitors (RAI) effectively protect against anthracycline-induced cardiotoxicity among cancer patients, preserving left ventricular ejection fraction (LVEF) and cutting cardiac events, according to a new study presented at the recently concluded 2019 Congress of the Asian Pacific Society of Cardiology (APSC).
Audrey Abella, 2 days ago
The taxane-based TPEx regimen demonstrated encouraging overall survival (OS) benefit for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) compared with the fluorouracil (5FU)-based EXTREME regimen, according to the results of the TPExtreme* trial presented at ASCO 2019.

Excerpts from the MY-COMPASSION Expert Meeting

30 Jan 2019
BTcP is defined as: “A transient exacerbation of pain that occurs either spontaneously, or in relation to a specific predictable or unpredictable trigger, despite relatively stable and adequately controlled background pain”.1,2 While there are various pain profiles associated with BTcP, a BTcP episode is typically severe, reaching peak pain intensity within 1–3 minutes from onset and is short in duration (ie, subsiding within 30 minutes).In Malaysia, opioids such as oral immediate-release(IR), intravenous (IV) and subcutaneous (SC) morphine are prescribed as ‘rescue’ medications for BTcP.2 IR opioids reach peak concentrations around 1 hour post-administration,and have a half-life of 3–6 hours, which may be suitable for longer duration BTcP episodes, but may not sufficiently address ‘sharp’, short-duration BTcP.2 In contrast, the faster onset of action seen in ROOs (eg, SLF which reaches peak plasma concentrations within 30–60 minutes post-administration) may be better suited for such episodes of BTcP.3,4

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 29 May 2019

AstraZeneca has announced plans to invest over US$125 million (RM500 million) in Malaysia over the next 5 years, with a focus on patient-centred innovation, local talent development and new robotic and cognitive technologies.

Tristan Manalac, 29 May 2019
Beta blockers (BB) and renin-angiotensin inhibitors (RAI) effectively protect against anthracycline-induced cardiotoxicity among cancer patients, preserving left ventricular ejection fraction (LVEF) and cutting cardiac events, according to a new study presented at the recently concluded 2019 Congress of the Asian Pacific Society of Cardiology (APSC).
Audrey Abella, 2 days ago
The taxane-based TPEx regimen demonstrated encouraging overall survival (OS) benefit for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) compared with the fluorouracil (5FU)-based EXTREME regimen, according to the results of the TPExtreme* trial presented at ASCO 2019.